Medtronic Return on Tangible Equity 2010-2025 | MDT
Current and historical return on tangible equity values for Medtronic (MDT) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Medtronic Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-07-31 | $4.66B | $-5.10B | -100.75% |
| 2025-04-30 | $4.66B | $-5.15B | -97.39% |
| 2025-01-31 | $4.26B | $-3.39B | -95.78% |
| 2024-10-31 | $4.29B | $-4.87B | -99.40% |
| 2024-07-31 | $3.93B | $-5.74B | -100.55% |
| 2024-04-30 | $3.68B | $-3.79B | -102.23% |
| 2024-01-31 | $4.20B | $-2.85B | -110.61% |
| 2023-10-31 | $4.10B | $-3.23B | -93.47% |
| 2023-07-31 | $3.62B | $-4.50B | -78.97% |
| 2023-04-30 | $3.76B | $-4.60B | -87.97% |
| 2023-01-31 | $4.06B | $-5.21B | -102.48% |
| 2022-10-31 | $4.32B | $-4.02B | -112.54% |
| 2022-07-31 | $5.21B | $-3.26B | -120.22% |
| 2022-04-30 | $5.04B | $-3.38B | -95.95% |
| 2022-01-31 | $4.91B | $-4.71B | -76.39% |
| 2021-10-31 | $4.70B | $-5.98B | -61.75% |
| 2021-07-31 | $3.88B | $-6.95B | -45.93% |
| 2021-04-30 | $3.61B | $-8.10B | -40.29% |
| 2021-01-31 | $2.89B | $-9.45B | -32.37% |
| 2020-10-31 | $3.54B | $-9.31B | -41.77% |
| 2020-07-31 | $4.41B | $-8.94B | -52.56% |
| 2020-04-30 | $4.79B | $-8.03B | -55.60% |
| 2020-01-31 | $5.32B | $-7.59B | -57.88% |
| 2019-10-31 | $4.67B | $-9.01B | -46.65% |
| 2019-07-31 | $4.42B | $-9.82B | -43.40% |
| 2019-04-30 | $4.63B | $-10.31B | -45.39% |
| 2019-01-31 | $4.92B | $-10.90B | -48.05% |
| 2018-10-31 | $2.26B | $-9.71B | -21.70% |
| 2018-07-31 | $3.16B | $-9.90B | -30.05% |
| 2018-04-30 | $3.10B | $-10.44B | -28.47% |
| 2018-01-31 | $2.81B | $-11.63B | -25.08% |
| 2017-10-31 | $5.02B | $-10.12B | -39.29% |
| 2017-07-31 | $4.12B | $-11.42B | -27.85% |
| 2017-04-30 | $4.03B | $-11.59B | -24.96% |
| 2017-01-31 | $3.97B | $-17.94B | -22.91% |
| 2016-10-31 | $4.24B | $-18.15B | -24.87% |
| 2016-07-31 | $3.65B | $-16.85B | -21.84% |
| 2016-04-30 | $3.54B | $-16.34B | -21.61% |
| 2016-01-31 | $2.43B | $-16.88B | -15.08% |
| 2015-10-31 | $2.32B | $-16.74B | -22.71% |
| 2015-07-31 | $2.62B | $-15.55B | -58.03% |
| 2015-04-30 | $2.68B | $-15.40B | 291.47% |
| 2015-01-31 | $3.12B | $6.88B | 48.74% |
| 2014-10-31 | $2.91B | $5.98B | 46.28% |
| 2014-07-31 | $2.98B | $6.21B | 48.04% |
| 2014-04-30 | $3.07B | $6.56B | 50.68% |
| 2014-01-31 | $3.59B | $6.39B | 61.57% |
| 2013-10-31 | $3.81B | $5.67B | 70.45% |
| 2013-07-31 | $3.56B | $5.57B | 68.71% |
| 2013-04-30 | $3.47B | $5.67B | 69.69% |
| 2013-01-31 | $3.49B | $4.74B | 74.36% |
| 2012-10-31 | $3.44B | $4.73B | 74.00% |
| 2012-07-31 | $3.66B | $4.76B | 82.45% |
| 2012-04-30 | $3.62B | $4.53B | 84.62% |
| 2012-01-31 | $3.40B | $4.54B | 83.57% |
| 2011-10-31 | $3.39B | $3.92B | 91.56% |
| 2011-07-31 | $3.09B | $4.10B | 85.00% |
| 2011-04-30 | $3.10B | $3.72B | 87.71% |
| 2011-01-31 | $3.28B | $3.07B | 93.07% |
| 2010-10-31 | $3.18B | $3.63B | 85.98% |
| 2010-07-31 | $3.48B | $3.70B | 98.22% |
| 2010-04-30 | $3.10B | $3.68B | 95.34% |
| 2010-01-31 | $2.25B | $3.80B | 75.92% |
| 2009-10-31 | $2.11B | $3.01B | 75.69% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $118.071B | $33.537B |
| Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.801B | 26.83 |
| Boston Scientific (BSX) | United States | $156.873B | 37.41 |
| Stryker (SYK) | United States | $150.304B | 30.59 |
| EssilorLuxottica (ESLOY) | France | $143.779B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.982B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.547B | 24.90 |
| ResMed (RMD) | United States | $41.283B | 29.52 |
| GE HealthCare Technologies (GEHC) | United States | $33.904B | 15.94 |
| Agilent Technologies (A) | United States | $33.716B | 21.78 |
| Terumo (TRUMY) | Japan | $26.887B | 31.86 |
| Koninklijke Philips (PHG) | Netherlands | $26.663B | 17.64 |
| Insulet (PODD) | United States | $23.536B | 78.86 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.155B | 13.47 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.315B | 0.00 |
| Baxter (BAX) | United States | $12.599B | 9.73 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.925B | 29.11 |
| Lantheus Holdings (LNTH) | United States | $3.865B | 10.45 |
| Envista Holdings (NVST) | United States | $3.530B | 24.70 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.295B | 14.62 |
| Perrigo (PRGO) | Ireland | $3.287B | 8.21 |
| ICU Medical (ICUI) | United States | $3.126B | 21.28 |
| Haemonetics (HAE) | United States | $2.651B | 11.83 |
| LeMaitre Vascular (LMAT) | United States | $2.166B | 46.45 |
| Curaleaf Holdings (CURLF) | Canada | $2.148B | 0.00 |
| Acuren (TIC) | United States | $2.126B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.886B | 11.87 |
| Green Thumb Industries (GTBIF) | United States | $1.876B | 80.57 |
| AtriCure (ATRC) | United States | $1.854B | 0.00 |
| Tilray Brands (TLRY) | Canada | $1.508B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.305B | 15.41 |
| Neogen (NEOG) | United States | $1.247B | 19.79 |
| AdaptHealth (AHCO) | United States | $1.246B | 17.71 |
| BioLife Solutions (BLFS) | United States | $1.218B | 2543.00 |
| InMode (INMD) | Israel | $0.960B | 8.88 |
| Kestra Medical Technologies (KMTS) | United States | $0.924B | 0.00 |
| Valneva SE (VALN) | France | $0.745B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.699B | 0.00 |
| SNDL (SNDL) | Canada | $0.665B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.611B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.595B | 0.00 |
| ZimVie (ZIMV) | United States | $0.535B | 20.62 |
| Evolus (EOLS) | United States | $0.490B | 0.00 |
| Surmodics (SRDX) | United States | $0.488B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.475B | 16.36 |
| CeriBell (CBLL) | United States | $0.425B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.380B | 0.00 |
| Owens & Minor (OMI) | United States | $0.378B | 3.35 |
| Canopy Growth (CGC) | Canada | $0.362B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.340B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.302B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.301B | 0.00 |
| High Tide (HITI) | Canada | $0.292B | 0.00 |
| Omeros (OMER) | United States | $0.289B | 0.00 |
| Brainsway (BWAY) | Israel | $0.288B | 58.69 |
| Capricor Therapeutics (CAPR) | United States | $0.286B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.278B | 21.12 |
| TriSalus Life Sciences (TLSI) | United States | $0.254B | 0.00 |
| Cerus (CERS) | United States | $0.251B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.244B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.238B | 0.00 |
| Organigram Global (OGI) | Canada | $0.224B | 0.00 |
| Quanterix (QTRX) | United States | $0.214B | 0.00 |
| Exagen (XGN) | United States | $0.210B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.196B | 16.34 |
| FitLife Brands (FTLF) | United States | $0.176B | 21.66 |
| Biote (BTMD) | United States | $0.166B | 5.51 |
| Jushi Holdings (JUSHF) | United States | $0.147B | 0.00 |
| Jin Medical (ZJYL) | China | $0.128B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.115B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Fonar (FONR) | United States | $0.098B | 12.66 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Apyx Medical (APYX) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Safety Shot (SHOT) | United States | $0.060B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.058B | 0.00 |
| ImmuCell (ICCC) | United States | $0.055B | 32.10 |
| Zynex (ZYXI) | United States | $0.051B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.051B | 0.00 |
| Veru (VERU) | United States | $0.048B | 0.00 |
| Nephros (NEPH) | United States | $0.043B | 33.75 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 14.45 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Allurion Technologies (ALUR) | United States | $0.016B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.015B | 0.00 |
| Sharps Technology (STSS) | United States | $0.015B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |